Last reviewed · How we verify
Dycal
Dycal is a Small molecule drug developed by Islamic Azad University, Sanandaj. It is currently in Phase 2 development. Also known as: chemical set calcium hydroxide.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Dycal |
|---|---|
| Also known as | chemical set calcium hydroxide |
| Sponsor | Islamic Azad University, Sanandaj |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparison Between Egyptian MTA, Biodentine Versus Calcium Hydroxide as Indirect Pulp Capping Materials In Permanent Teeth (PHASE4)
- Effectiveness of Biodentine v/s Calcium Hydroxide as Indirect Pulp Capping Materials (NA)
- Retrospective Evaluation of the Results of Direct Pulp Capping Treatment
- Clinical Investigation of Effectiveness of a Calcium Silicate Cement (NA)
- Clinical Comparison of Vital Pulp Capping Restorative Protocols (NA)
- Direct Pulp Capping in Primary Molars (PHASE3)
- Clinical And Radiographic Evaluation Of Premixed Bio-ceramic MTA In Indirect Pulp Capping Of Young Permanent Molars (PHASE3)
- Calcium Silicate Versus Calcium Hydroxide in Two-step Indirect Pulp Treatment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dycal CI brief — competitive landscape report
- Dycal updates RSS · CI watch RSS
- Islamic Azad University, Sanandaj portfolio CI
Frequently asked questions about Dycal
What is Dycal?
Who makes Dycal?
Is Dycal also known as anything else?
What development phase is Dycal in?
Related
- Manufacturer: Islamic Azad University, Sanandaj — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: chemical set calcium hydroxide
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing